Graeme Smith, South Africa's director of cricket and former Test captain, has hit back through his lawyer at accusations of racial prejudice contained in a report by an ombudsman.
David Becker, former International Cricket Council head of legal and Smith's personal lawyer, issued a statement on Friday in which he disputed findings by Advocate Dumisa Ntsebeza, who headed a Social Justice and Nation Building Commission (SJN) to investigate allegations of racial discrimination in South African cricket.
In a report issued on Wednesday, Ntsebeza found that Smith "failed to rebut the presumption of unfair discrimination" in appointing former Test wicketkeeper and long-time team-mate Boucher as head coach of the national team ahead of Enoch Nkwe, a black coach who served briefly as national team director.
"Some of the findings are entirely questionable and without any basis," said Becker, who claimed that lawyers for "various respondents" had raised "material concerns" about the integrity of the SJN process.
"Important parts of the evidence are simply not dealt with in the report," said Becker.
"For example, the ombudsman states that Smith did not explain why he appointed Boucher in his evidence. However, the reasons are clearly addressed by Smith and (former CSA president) Mr (Chris) Nenzani in their affidavits submitted to the SJN."
Ntsebeza also found that Smith's appointment was irregular and that a refusal to report to then chief executive Thabang Moroe, who was later dismissed for misconduct, was evidence of "racial bias against black leadership".
Becker pointed out that Smith did not appoint himself and that his appointment was approved by the national selectors, the entire board of CSA and senior executives of the organisation.
He had worked happily with Moroe's acting successor, who was black, and three black presidents.
Becker did not directly address an accusation of racial bias in the decision when Smith was captain to use star batsman AB de Villiers as wicketkeeper in a Test series in England in 2012, ahead of black reserve wicketkeeper Thami Tsolekile.
But Becker said CSA would have to consider "a number of fundamental flaws" in the process of the hearings.
"For instance, how do you make far-reaching and public findings of racial prejudice against certain people and in the same breath say that they are ‘tentative’, as the ombudsman has done?
"How is CSA expected to implement those findings when the ombudsman has said, by his own admission, that he 'cannot make definitive findings in an instance where the evidence of both the so-called victims and the alleged perpetrators was not tested'?
"Why wasn't the evidence properly tested? The ombudsman had the opportunity to cross examine the witnesses under the terms of reference and didn't take that opportunity," said Becker.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.